Ovarian Cancer

There are 3 PARP inhibitors that are FDA approved in multiple settings of ovarian cancer.

STRO-002 is a folate receptor alpha-targeting antibody drug conjugate for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of systemic therapy.

The designation highlights the need for new treatment options for patients with platinum-resistant ovarian cancer and the significant treatment potential of IN10018, according to a press release from InxMed, the manufacturer of the novel drug.

The OVATION 2 study combines GEN-1 with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with stage 3 and 4 ovarian cancer.

Oncologist Susan Miesfeldt, MD, of MaineHealth, discussed the importance of genetic testing and counseling for breast and ovarian cancers as well as barriers that must be addressed in order to reach more patients eligible for these services.

This discovery could enhance efforts to develop better treatments for breast, ovarian, and prostate cancer.

Olaparib and niraparib both show promise in the maintenance treatment of ovarian cancer, though they may each be appropriate for different patient populations.

The safety profile was consistent with the profiles associated with each drug as a monotherapy, with no clinically significant drug-drug interactions observed with the combination.

Study indicates patients with ovarian cancer frequently receive aggressive end-of-life care despite industry guidelines that emphasize quality of life for those with advanced disease.

Guidelines typically recommend debulking surgery, plus systemic chemotherapy for most patients.

The company received Fast Track designation from the FDA for GEN-1, a DNA-mediated interleukin-12 (IL-12) immunotherapy.

The FDA has granted a fast track designation to the DNA-mediated interleukin-12 immunotherapy GEN-1 for use in the treatment of patients with advanced ovarian cancer.

Rucaparib is an oral, small molecule inhibitor being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers.

FDA approves FoundationOne Liquid CDx as a companion diagnostic for alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.

A first-in-class targeted therapy, VB-111 is administered by intravenous infusion once every 6 to 8 weeks.

Several recent studies presented at the virtual SGO 2020 Annual Meeting on Women’s Cancer looked into veliparib, a potential anticancer PARP inhibitor, for treatment of various types of ovarian cancer.

Pharmacy Times spoke with Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, about how the drug niraparib could affect treatment options for patients with ovarian cancer.

The JAVELIN trial is a randomized, open-label, phase 3 trial comparing avelumab in combination with chemotherapy versus chemotherapy alone.

Researchers presented findings in conjunction with the Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer on the phase 3 VELIA trial studying the safety of veliparib.

PARP inhibitors are novel therapies with indication focused on ovarian cancer; however, new agents are being studied for other cancers as well.

Clinical trials are now evaluating the potential combination of PARP inhibitors with immunotherapy or other agents in patients with ovarian cancer.

Ovarian cancer has been dubbed "the silent killer" because of its overall 5-year survival rate of 47%: By the time a woman receives the diagnosis, the prognosis is unfavorable.